CytomX Therapeutics, Inc. (CTMX) DCF Valuation

CytomX Therapeutics, Inc. (CTMX) DCF Valuation
  • ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
  • ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
  • ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
  • ✓ Aucune Expertise N'Est Requise; Facile À Suivre

CytomX Therapeutics, Inc. (CTMX) Bundle

DCF model
Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Discover the true value of CytomX Therapeutics, Inc. (CTMX) with our advanced DCF Calculator! Adjust key assumptions, explore various scenarios, and evaluate how changes affect CytomX's valuation – all within a single Excel template.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue 57.5 100.4 69.6 53.2 101.2 129.2 165.0 210.6 268.9 343.4
Revenue Growth, % 0 74.58 -30.68 -23.59 90.38 27.67 27.67 27.67 27.67 27.67
EBITDA -138.9 -78.0 -113.3 -98.9 -4.3 -98.7 -126.0 -160.9 -205.4 -262.3
EBITDA, % -241.57 -77.69 -162.9 -186.02 -4.26 -76.39 -76.39 -76.39 -76.39 -76.39
Depreciation 2.6 5.5 5.8 5.9 2.2 8.1 10.4 13.3 17.0 21.7
Depreciation, % 4.53 5.44 8.39 11.02 2.15 6.31 6.31 6.31 6.31 6.31
EBIT -141.5 -83.4 -119.2 -104.7 -6.5 -100.7 -128.5 -164.1 -209.5 -267.5
EBIT, % -246.1 -83.13 -171.29 -197.03 -6.41 -77.91 -77.91 -77.91 -77.91 -77.91
Total Cash 296.1 316.1 305.2 193.7 174.5 129.2 165.0 210.6 268.9 343.4
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables .0 .8 .8 36.0 3.4
Account Receivables, % 0.02261302 0.79512 1.14 67.69 3.39
Inventories .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Inventories, % 0.000001739463 0.000000996 0.000001437339 0 0 0.000000835 0.000000835 0.000000835 0.000000835 0.000000835
Accounts Payable 4.2 3.0 2.8 2.8 1.5 5.4 6.9 8.8 11.3 14.4
Accounts Payable, % 7.23 2.99 4.05 5.28 1.44 4.2 4.2 4.2 4.2 4.2
Capital Expenditure -3.5 -2.3 -1.6 -1.7 -.8 -3.8 -4.9 -6.2 -8.0 -10.2
Capital Expenditure, % -6.08 -2.3 -2.31 -3.27 -0.82992 -2.96 -2.96 -2.96 -2.96 -2.96
Tax Rate, % 117.12 117.12 117.12 117.12 117.12 117.12 117.12 117.12 117.12 117.12
EBITAT -140.9 -58.6 -115.0 -102.6 1.1 -73.3 -93.6 -119.6 -152.6 -194.9
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -137.6 -57.4 -110.9 -133.7 33.6 -80.5 -91.8 -117.3 -149.7 -191.2
WACC, % 8.7 8.51 8.68 8.69 8.04 8.52 8.52 8.52 8.52 8.52
PV UFCF
SUM PV UFCF -478.8
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) -195
Terminal Value -2,989
Present Terminal Value -1,986
Enterprise Value -2,464
Net Debt -3
Equity Value -2,461
Diluted Shares Outstanding, MM 74
Equity Value Per Share -33.35

What You Will Get

  • Pre-Filled Financial Model: CytomX Therapeutics’ actual data enables precise DCF valuation.
  • Full Forecast Control: Adjust revenue growth, margins, WACC, and other key drivers specific to (CTMX).
  • Instant Calculations: Automatic updates ensure you see results as you make changes to your projections.
  • Investor-Ready Template: A refined Excel file designed for professional-grade valuation of (CTMX).
  • Customizable and Reusable: Tailored for flexibility, allowing repeated use for detailed forecasts of (CTMX).

Key Features

  • Customizable Clinical Parameters: Adjust essential inputs such as patient enrollment rates, trial durations, and treatment costs.
  • Instant Valuation Insights: Generates intrinsic value, net present value (NPV), and additional metrics on demand.
  • High-Precision Forecasting: Utilizes CytomX’s actual clinical data for accurate valuation projections.
  • Simplified Scenario Testing: Easily evaluate various hypotheses and analyze results side by side.
  • Efficiency Booster: Remove the hassle of constructing intricate valuation models from the ground up.

How It Works

  1. Step 1: Download the Excel file.
  2. Step 2: Review pre-entered CytomX Therapeutics data (historical and projected).
  3. Step 3: Adjust key assumptions (yellow cells) based on your analysis.
  4. Step 4: View automatic recalculations for CytomX Therapeutics' intrinsic value.
  5. Step 5: Use the outputs for investment decisions or reporting.

Why Choose CytomX Therapeutics, Inc. (CTMX) Calculator?

  • All-in-One Solution: Combines DCF, WACC, and financial ratio evaluations tailored for CytomX Therapeutics.
  • Flexible Inputs: Modify the highlighted fields to explore different financial scenarios.
  • In-Depth Analysis: Automatically computes CytomX’s intrinsic value and Net Present Value.
  • Integrated Data: Historical and projected figures provide a solid foundation for analysis.
  • Expert-Level Tool: Perfect for financial analysts, investors, and industry consultants focused on biotechnology.

Who Should Use CytomX Therapeutics, Inc. (CTMX)?

  • Investors: Gain insights into innovative cancer therapies with a focus on targeted treatments.
  • Healthcare Analysts: Utilize comprehensive data to evaluate the potential of pipeline products.
  • Consultants: Tailor research findings for client briefings or strategic planning sessions.
  • Biotech Enthusiasts: Expand your knowledge of therapeutic development through case studies and real-world applications.
  • Educators and Students: Leverage it as a resource for learning about biotech advancements in academic settings.

What the Template Contains

  • Preloaded CTMX Data: Historical and projected financial data, including revenue, EBIT, and capital expenditures.
  • DCF and WACC Models: Professional-grade sheets for calculating intrinsic value and Weighted Average Cost of Capital.
  • Editable Inputs: Yellow-highlighted cells for adjusting revenue growth, tax rates, and discount rates.
  • Financial Statements: Comprehensive annual and quarterly financials for deeper analysis.
  • Key Ratios: Profitability, leverage, and efficiency ratios to evaluate performance.
  • Dashboard and Charts: Visual summaries of valuation outcomes and assumptions.

No products were found matching.